Skip to main content

Incidence of Acute Respiratory Failure (ARF) following Trimethoprim-Sulfamethoxazole (TMP-SMX) Use: A Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Medical Product
trimethoprim-sulfamethoxazole
Health Outcome(s)
acute respiratory failure
Description

In this report we examined counts of individuals using trimethoprim-sulfamethoxazole (TMP-SMX) and rates of acute respiratory failure (ARF) during treatment. We assessed indications for TMP-SMX dispensing as well as concurrent diagnoses at the time of ARF diagnoses. We repeated the analyses for four other antibiotics of interest.

The study period included data from January 1, 2000 to December 31, 2019. We distributed this request to 14 Data Partners on May 15, 2020.

Deliverables (1)
Sentinel Modular Program Report: Incidence of Acute Respiratory Failure (ARF) following Trimethoprim-Sulfamethoxazole (TMP-SMX) Use: A Descriptive Analysis
Additional Details
FDA Center
CDER
Time Period
January 1, 2000 - December 31, 2019
Analysis Type
Descriptive
Population / Cohort
Individuals 6 months to 64 years of age
Data Sources
Sentinel Distributed Database (SDD)